Jennifer W Bea1, Peter W Jurutka2, Elizabeth A Hibler3, Peter Lance1, Maria E Martínez4, Denise J Roe5, Christine L Sardo Molmenti6, Patricia A Thompson1, Elizabeth T Jacobs7. 1. University of Arizona Cancer Center, 1515N. Campbell Avenue, Tucson, AZ 85724-5024, USA. 2. School of Mathematical and Natural Sciences, Arizona State University, 4701W. Thunderbird Rd, Phoenix, AZ 85306, USA. 3. Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2220 Pierce Ave, Nashville, TN 37232, USA; Mel and Enid Zuckerman College of Public Health, 1295N. Martin Ave., Tucson, AZ, 85724, USA. 4. UCSD Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA. 5. University of Arizona Cancer Center, 1515N. Campbell Avenue, Tucson, AZ 85724-5024, USA; Mel and Enid Zuckerman College of Public Health, 1295N. Martin Ave., Tucson, AZ, 85724, USA. 6. Mailman School of Public Health, Columbia University, 722W 168th St, New York, NY 10032, USA. 7. University of Arizona Cancer Center, 1515N. Campbell Avenue, Tucson, AZ 85724-5024, USA; Mel and Enid Zuckerman College of Public Health, 1295N. Martin Ave., Tucson, AZ, 85724, USA. Electronic address: jacobse@email.arizona.edu.
Abstract
AIM: Few epidemiological studies have investigated the association between circulating concentrations of the active vitamin D metabolite 1,25(OH)2D and metabolic syndrome. We sought to determine whether blood levels of 1,25(OH)2D are associated with metabolic syndrome and its individual components, including waist circumference, triglycerides, blood pressure, and glucose, and high-density lipoprotein. We also investigated these associations for the more abundant precursor vitamin D metabolite, 25(OH)D. METHODS: Participants from two completed clinical trials of colorectal neoplasia with available metabolic syndrome data and blood samples for measurement of 1,25(OH)2D (n=1048) and 25(OH)D (n=2096) were included. Cross-sectional analyses of the association between concentrations of 1,25(OH)2D, 25(OH)D, metabolic syndrome, and its components were conducted. RESULTS: A statistically significant inverse association was observed for circulating concentrations of 1,25(OH)2D and metabolic syndrome, with adjusted ORs (95% CIs) of 0.73 (0.52-1.04) and 0.52 (0.36-0.75) for the second and third tertiles of 1,25(OH)2D, respectively (p-trend <0.001). Significant inverse relationships were also observed between 1,25(OH)2D and high triglycerides (p-trend <0.001), and low high-density lipoprotein (p-trend <0.001). For 25(OH)D concentrations, significant inverse associations were found for metabolic syndrome (p-trend <0.01), high waist circumference (p-trend <0.04) and triglyceride levels (p-trend <0.01). Participants with 25(OH)D ≥30 ng/ml and in the highest tertile of 1,25(OH)2D demonstrated significantly lower odds of metabolic syndrome, with an OR (95% CI) of 0.38 (0.19-0.75) compared to those in the lowest category for both metabolites. CONCLUSION: These results provide new evidence that the relatively rarely-studied active hormonal form of vitamin D, 1,25(OH)2D, is associated with metabolic syndrome and its components, and confirm prior findings for 25(OH)D. The finding that 1,25(OH)2D is related to high-density lipoprotein, while 25(OH)D is not, suggests that there may be an independent mechanism of action for 1,25(OH)2D in relation to metabolic dysregulation.
AIM: Few epidemiological studies have investigated the association between circulating concentrations of the active vitamin D metabolite 1,25(OH)2D and metabolic syndrome. We sought to determine whether blood levels of 1,25(OH)2D are associated with metabolic syndrome and its individual components, including waist circumference, triglycerides, blood pressure, and glucose, and high-density lipoprotein. We also investigated these associations for the more abundant precursor vitamin D metabolite, 25(OH)D. METHODS:Participants from two completed clinical trials of colorectal neoplasia with available metabolic syndrome data and blood samples for measurement of 1,25(OH)2D (n=1048) and 25(OH)D (n=2096) were included. Cross-sectional analyses of the association between concentrations of 1,25(OH)2D, 25(OH)D, metabolic syndrome, and its components were conducted. RESULTS: A statistically significant inverse association was observed for circulating concentrations of 1,25(OH)2D and metabolic syndrome, with adjusted ORs (95% CIs) of 0.73 (0.52-1.04) and 0.52 (0.36-0.75) for the second and third tertiles of 1,25(OH)2D, respectively (p-trend <0.001). Significant inverse relationships were also observed between 1,25(OH)2D and high triglycerides (p-trend <0.001), and low high-density lipoprotein (p-trend <0.001). For 25(OH)D concentrations, significant inverse associations were found for metabolic syndrome (p-trend <0.01), high waist circumference (p-trend <0.04) and triglyceride levels (p-trend <0.01). Participants with 25(OH)D ≥30 ng/ml and in the highest tertile of 1,25(OH)2D demonstrated significantly lower odds of metabolic syndrome, with an OR (95% CI) of 0.38 (0.19-0.75) compared to those in the lowest category for both metabolites. CONCLUSION: These results provide new evidence that the relatively rarely-studied active hormonal form of vitamin D, 1,25(OH)2D, is associated with metabolic syndrome and its components, and confirm prior findings for 25(OH)D. The finding that 1,25(OH)2D is related to high-density lipoprotein, while 25(OH)D is not, suggests that there may be an independent mechanism of action for 1,25(OH)2D in relation to metabolic dysregulation.
Authors: D S Alberts; M E Martínez; D J Roe; J M Guillén-Rodríguez; J R Marshall; J B van Leeuwen; M E Reid; C Ritenbaugh; P A Vargas; A B Bhattacharyya; D L Earnest; R E Sampliner Journal: N Engl J Med Date: 2000-04-20 Impact factor: 91.245
Authors: J W Welberg; J F Monkelbaan; E G de Vries; F A Muskiet; A Cats; E T Oremus; W Boersma-van Ek; H van Rijsbergen; R van der Meer; N H Mulder Journal: Ann Nutr Metab Date: 1994 Impact factor: 3.374
Authors: Elizabeth A Hibler; Christine L Sardo Molmenti; Peter Lance; Peter W Jurutka; Elizabeth T Jacobs Journal: Cancer Causes Control Date: 2014-04-16 Impact factor: 2.506
Authors: Seung Joo Chon; Bo Hyon Yun; Yeon Soo Jung; Si Hyun Cho; Young Sik Choi; Suk Young Kim; Byung Seok Lee; Seok Kyo Seo Journal: PLoS One Date: 2014-02-21 Impact factor: 3.240
Authors: S Salekzamani; H Mehralizadeh; A Ghezel; Y Salekzamani; M A Jafarabadi; A S Bavil; B P Gargari Journal: J Endocrinol Invest Date: 2016-07-11 Impact factor: 4.256
Authors: Thais C Maia-Ceciliano; Andre R C Barreto-Vianna; Sandra Barbosa-da-Silva; Marcia B Aguila; Tatiane S Faria; Carlos A Mandarim-de-Lacerda Journal: Endocrine Date: 2016-05-03 Impact factor: 3.633
Authors: Elizabeth A Hibler; Christine L Sardo Molmenti; Qi Dai; Lindsay N Kohler; Shaneda Warren Anderson; Peter W Jurutka; Elizabeth T Jacobs Journal: Bone Date: 2015-11-24 Impact factor: 4.398
Authors: Lindsay N Kohler; Elizabeth A Hibler; Robin B Harris; Eyal Oren; Denise J Roe; Peter W Jurutka; Elizabeth T Jacobs Journal: J Nutr Date: 2017-01-25 Impact factor: 4.798
Authors: Margot J Overman; Neil Pendleton; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Joseph D Finn; Gianni Forti; Giulia Rastrelli; Aleksander Giwercman; Thang S Han; Ilpo T Huhtaniemi; Krzysztof Kula; Michael E J Lean; Margus Punab; David M Lee; Elon S Correa; Tomas Ahern; Sabine M P Verschueren; Leen Antonio; Evelien Gielen; Martin K Rutter; Dirk Vanderschueren; Frederick C W Wu; Jos Tournoy Journal: Eur J Nutr Date: 2016-07-01 Impact factor: 5.614